Compare Cintas Corporation (CTAS) vs Enveric Biosciences Inc (ENVB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cintas Corporation vs Enveric Biosciences Inc — how do they compare? Cintas Corporation trades at $186.68 (market cap $73.76B), while Enveric Biosciences Inc trades at $1.25 (market cap $5.32M). The key difference: Cintas Corporation is far larger — about 13864.7× Enveric Biosciences Inc's market cap, and Cintas Corporation pays a 0.98% dividend while Enveric Biosciences Inc pays none. Which is the better fit depends on your goals.
| CTAS | ENVB | |
|---|---|---|
Market Cap | $73.76B | $5.32M |
Sector | Industrials | Health |
52-Week High | $226.27 | $17.40 |
52-Week Low | $163.55 | $1.28 |
Enterprise Value | $76.49B | $408.82K |
Dividend Yield | 0.98% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Cintas (CTAS) trades at $183.75, up 2.29% on the day, with a bullish technical outlook supported by moving averages and strong support at $182. The company shows robust fundamentals with revenue growing to $10.34B in 2025 and net income reaching $1.81B, though valuation ratios like P/E of 38.77 appear elevated. Recent news highlights upcoming Q4 earnings and continued recognition as a top employer.
The stock offers a compelling growth story with consistent earnings beats and a 43-year dividend growth track record, but faces risks from high valuation and economic sensitivity. Analyst consensus is mixed with a $212.50 price target, suggesting moderate upside potential if execution remains strong amid competitive pressures.
ENVB trades at $1.33, down 1.48% on the day, with a bearish technical signal from moving averages despite neutral oscillators. The company shows significant financial challenges with negative ROE of -257.95% and ROA of -218.01%, though it has consistently beaten earnings expectations in recent quarters. Recent news highlights active participation in investor conferences and progress with EB-003 drug candidate development.
While analyst consensus is 75% buy-rated, the stock faces substantial fundamental risks from negative profitability and cash burn. Investment opportunity exists if clinical developments succeed, but shareholders should weigh high operational losses against potential biotech breakthroughs in the neuroplastogenic therapeutics space.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Cintas Corporation
In its core uniform and facility services unit (78% of sales), Cintas provides uniform rental programs to businesses across the size spectrum, mostly in North America. The firm is by far the largest provider in the industry. Facilities products generally include the rental and sale of entrance mat, mops, shop towels, hand sanitizers, and restroom supplies. Cintas also runs a first aid and safety services business (11% of sales), a fire protection services business (7% of sales), and a uniform direct sales business (4% of sales).
Read more on CTAS →About Enveric Biosciences Inc
Enveric Biosciences is a biotechnology company focused on developing next-generation psychedelic-inspired therapies for mental health and neuropsychiatric disorders.
Read more on ENVB →
